A Test-based Strategy Is More Cost Effective Than Empiric Dose Escalation for Patients With Crohn's Disease Who Lose Responsiveness to Infliximab - Concepedia

Concepedia

Publication | Open Access

A Test-based Strategy Is More Cost Effective Than Empiric Dose Escalation for Patients With Crohn's Disease Who Lose Responsiveness to Infliximab

DOI Full Paper Access

176

Citations

31

References

2013

Year

Fernando Velayos, James G. Kahn, William J. Sandborn, Brian G. Feagan

Clinical Gastroenterology and Hepatology

Clinical EffectivenessTest-based StrategyGastroenterologyRandomized Controlled TrialUlcerative ColitisDrug TrialMedicine

References

	Year	Citations

Page 1